Anti-Hypertensive Therapeutics Industry Analysis and Trend in Asia-Pacific Markets to 2021

Researchmoz added Most up-to-date research on "Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021" to its huge collection of research reports.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=288677

Scope

Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.

Will generics continue to dominate treatment?

How do the elderly populations and their associated risk factors affect prevalence?

The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of...